Background: Neuropsychiatric Symptoms (NPS) including aggression, psychosis, anxiety, apathy and depression are highly prevalent in Alzheimer's Disease patients and are associated with accelerated decline and a detrimental impact on suffering and quality of life of both patients and caregivers. There are no effective pharmaceutical interventions targeting these symptoms, making a better understanding of the etiologic mechanisms underlying NPS in AD critical to develop improved treatments.
Method: To facilitate identification of genetic loci and mechanistic pathways underlying NPS in AD, we have initiated an effort (NIH: U01AG079850) to collate and harmonize all available NPS data in over 70 cohorts (>80,000 samples) of diverse ancestries with whole-genome sequencing data from the Alzheimer's Disease Sequencing Project (ADSP), and analyze these data to identify genetic loci and mechanistic pathways associated with NPS in AD.
Result: A publicly available genomics resource for NPS in AD with extensive harmonized NPS phenotype data. Primary core analyses will (1) identify novel genetic risk factors associated with neuropsychiatric symptoms in AD, (2) characterize the shared genetic architecture of neuropsychiatric symptoms in AD and primary psychiatric disorders, and (3) assess the role of ancestry effects in the etiology of neuropsychiatric symptoms in AD.
Conclusion: Expansion of the ADSP to harmonized and refined NPS phenotypes coupled with the proposed core analyses will lay the foundation to disentangle the molecular mechanisms underlying these detrimental symptoms in AD in diverse populations.
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.